MX382549B - Combinación con anticuerpos anti-cd40 y anticuerpos anti-pd-1. - Google Patents

Combinación con anticuerpos anti-cd40 y anticuerpos anti-pd-1.

Info

Publication number
MX382549B
MX382549B MX2017001864A MX2017001864A MX382549B MX 382549 B MX382549 B MX 382549B MX 2017001864 A MX2017001864 A MX 2017001864A MX 2017001864 A MX2017001864 A MX 2017001864A MX 382549 B MX382549 B MX 382549B
Authority
MX
Mexico
Prior art keywords
antibodies
combination
antigen
antibody
relates
Prior art date
Application number
MX2017001864A
Other languages
English (en)
Spanish (es)
Other versions
MX2017001864A (es
Inventor
Niina Veitonmäki
Per Norlen
Peter Ellmark
Original Assignee
Alligator Bioscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX382549(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1414270.7A external-priority patent/GB201414270D0/en
Priority claimed from GBGB1507541.9A external-priority patent/GB201507541D0/en
Application filed by Alligator Bioscience Ab filed Critical Alligator Bioscience Ab
Publication of MX2017001864A publication Critical patent/MX2017001864A/es
Publication of MX382549B publication Critical patent/MX382549B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017001864A 2014-08-12 2015-08-12 Combinación con anticuerpos anti-cd40 y anticuerpos anti-pd-1. MX382549B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1414270.7A GB201414270D0 (en) 2014-08-12 2014-08-12 Antibodies
GB201422614 2014-12-18
GBGB1507541.9A GB201507541D0 (en) 2015-05-01 2015-05-01 Antibodies
PCT/EP2015/068598 WO2016023960A1 (en) 2014-08-12 2015-08-12 Combination therapies with anti cd40 antibodies

Publications (2)

Publication Number Publication Date
MX2017001864A MX2017001864A (es) 2017-08-02
MX382549B true MX382549B (es) 2025-03-13

Family

ID=53836090

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001864A MX382549B (es) 2014-08-12 2015-08-12 Combinación con anticuerpos anti-cd40 y anticuerpos anti-pd-1.

Country Status (25)

Country Link
US (3) US11149090B2 (enExample)
EP (3) EP4653463A3 (enExample)
JP (1) JP6654187B2 (enExample)
KR (1) KR102443258B1 (enExample)
CN (3) CN114099671A (enExample)
AU (1) AU2015303164B2 (enExample)
CA (1) CA2957146A1 (enExample)
CL (1) CL2017000335A1 (enExample)
CO (1) CO2017001317A2 (enExample)
CR (1) CR20170096A (enExample)
DK (1) DK3180087T3 (enExample)
EA (1) EA201790339A1 (enExample)
EC (1) ECSP17008984A (enExample)
ES (1) ES2725463T3 (enExample)
IL (1) IL250512B (enExample)
MA (1) MA47472A (enExample)
MX (1) MX382549B (enExample)
NI (1) NI201700015A (enExample)
PE (1) PE20170680A1 (enExample)
PH (1) PH12017500229A1 (enExample)
SG (1) SG11201701070WA (enExample)
SV (1) SV2017005380A (enExample)
UA (1) UA119783C2 (enExample)
WO (1) WO2016023960A1 (enExample)
ZA (1) ZA201701126B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
WO2014124134A1 (en) 2013-02-07 2014-08-14 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
CA2985816A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3340999A4 (en) 2015-08-28 2019-06-12 The General Hospital Corporation AGONISTIC ANTI-TUMOR NECROSIS RECEPTOR 2 ANTIBODIES
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
CA3253342A1 (en) * 2016-05-13 2026-03-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
UA128304C2 (uk) * 2016-07-14 2024-06-05 Ґенмаб А/С Мультиспецифічне антитіло до cd40 і cd137
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
WO2018078620A1 (en) 2016-10-25 2018-05-03 Urogen Pharma Ltd. Immunomodulating treatments of body cavities
JP2019534292A (ja) * 2016-11-02 2019-11-28 アペクシジェン， インコーポレイテッド 組み合わせた抗ｃｄ４０抗体および使用方法
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
ES2902670T3 (es) * 2017-01-13 2022-03-29 Taizhou Hanzhong Biopharmaceutics Inc Anticuerpo monoclonal contra PD-1 y aplicaciones del mismo
WO2018160917A1 (en) * 2017-03-03 2018-09-07 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
IL272159B2 (en) 2017-08-04 2026-03-01 Genmab As PD-L1 and CD137 binding agents and their use
CA3071217A1 (en) 2017-08-31 2019-03-07 Multimmune Gmbh Hsp70 based combination therapy
US20210283168A1 (en) * 2018-03-13 2021-09-16 Hibercell, Inc. Beta glucan and cd40 agonist combination immunotherapy
WO2019241306A2 (en) * 2018-06-12 2019-12-19 Neon Therapeutics, Inc. Combination therapy with neoantigen vaccine
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
CA3109905A1 (en) * 2018-08-20 2020-02-27 Pfizer Inc. Anti-gdf15 antibodies, compositions and methods of use
CA3109954A1 (en) 2018-08-20 2020-02-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP7652690B2 (ja) 2018-11-15 2025-03-27 ザ ジェネラル ホスピタル コーポレイション アゴニスト性腫瘍壊死因子受容体スーパーファミリーポリペプチド
MA55132A (fr) 2018-11-23 2022-03-02 Strike Pharma Ab Conjugués bi-spécifiques
BR112021009835A2 (pt) * 2018-11-30 2021-08-17 Jiangsu Hengrui Medicine Co., Ltd. anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
MX2021014572A (es) * 2019-05-28 2022-03-17 Janssen Biotech Inc Metodo para proporcionar la administracion segura de un anticuerpo anti-cd40.
US20220370418A1 (en) 2019-09-09 2022-11-24 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4083210A1 (en) * 2019-12-27 2022-11-02 Interoligo Corporation Anti-cancer immunotherapeutic composition for treating cancer
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022002065A1 (zh) * 2020-06-30 2022-01-06 百奥泰生物制药股份有限公司 抗cd40抗体或抗原结合片段及其应用
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
WO2023064878A1 (en) * 2021-10-15 2023-04-20 The Rockefeller University Combination of anti-cd40 antibody and il-15 for treating cancer
JP2024539940A (ja) * 2021-10-26 2024-10-31 ナビキュア バイオファーマシューティカルズ リミテッド がん及び感染症に対する組み合わせ療法
JP2025521028A (ja) 2022-06-23 2025-07-04 アリゲーター・バイオサイエンス・アーベー 併用療法
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
JP4430303B2 (ja) 2000-12-12 2010-03-10 アリゲーター・バイオサイエンス・アーベー タンパク質機能のインビトロ分子進化方法
EP2011802A3 (en) 2001-04-27 2009-04-15 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
CA2485506C (en) 2002-05-17 2012-02-28 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
AU2005323515A1 (en) 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
EP1885399B1 (en) 2005-05-26 2010-10-20 Seattle Genetics, Inc. Humanized anti-cd40 antibodies and their methods of use
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
EP2245065A1 (en) 2008-01-23 2010-11-03 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
CN102170908A (zh) * 2008-08-29 2011-08-31 莱顿大学医学中心附属莱顿教学医院 向个体的肿瘤引流淋巴结递送cd40激动剂
US9217100B2 (en) * 2009-09-16 2015-12-22 The Chemours Company Fc, Llc Chiller apparatus containing trans-1,1,1,4,4,4-hexafluoro-2-butene and methods of producing cooling therein
GB201006096D0 (en) 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
EP2739358B1 (en) 2011-08-01 2018-11-28 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US10533054B2 (en) * 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
WO2015091655A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Combination therapy with an anti-ang2 antibody and a cd40 agonist
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
MY188749A (en) 2015-04-17 2021-12-28 Bristol Myers Squibb Co Compositions comprising a combination of nivolumab and ipilimumab
RU2715597C2 (ru) 2015-05-29 2020-03-02 Эббви Инк. Антитела к cd40 и способы их применения
US10479838B2 (en) 2015-06-29 2019-11-19 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
KR102671348B1 (ko) 2015-06-29 2024-05-30 브리스톨-마이어스 스큅 컴퍼니 Cd40에 대한 항체

Also Published As

Publication number Publication date
US20210403589A1 (en) 2021-12-30
NI201700015A (es) 2017-05-12
ZA201701126B (en) 2025-08-27
EP3180087A1 (en) 2017-06-21
CR20170096A (es) 2017-06-15
KR20170041790A (ko) 2017-04-17
US12570753B2 (en) 2026-03-10
AU2015303164A1 (en) 2017-03-09
BR112017002729A2 (pt) 2018-02-27
EP3552665A2 (en) 2019-10-16
JP2017524715A (ja) 2017-08-31
EA201790339A1 (ru) 2017-06-30
IL250512A0 (en) 2017-03-30
US20240228643A9 (en) 2024-07-11
IL250512B (en) 2021-08-31
UA119783C2 (uk) 2019-08-12
CL2017000335A1 (es) 2017-08-11
DK3180087T3 (da) 2019-05-13
PH12017500229A1 (en) 2017-07-10
US20170226217A1 (en) 2017-08-10
KR102443258B1 (ko) 2022-09-14
CA2957146A1 (en) 2016-02-18
CO2017001317A2 (es) 2017-08-10
NZ729270A (en) 2024-03-22
MA47472A (fr) 2019-12-18
ES2725463T3 (es) 2019-09-24
EP4653463A3 (en) 2026-02-25
MX2017001864A (es) 2017-08-02
US11149090B2 (en) 2021-10-19
ECSP17008984A (es) 2017-05-31
SG11201701070WA (en) 2017-03-30
EP3552665A3 (en) 2019-12-18
JP6654187B2 (ja) 2020-02-26
WO2016023960A1 (en) 2016-02-18
PE20170680A1 (es) 2017-06-14
US20240132609A1 (en) 2024-04-25
CN114099671A (zh) 2022-03-01
CN119280407A (zh) 2025-01-10
AU2015303164B2 (en) 2020-10-29
SV2017005380A (es) 2018-09-14
EP4653463A2 (en) 2025-11-26
CN106573981A (zh) 2017-04-19
EP3180087B1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
ZA201701126B (en) Combination therapies with anti cd40 antibodies
MX2022002364A (es) Anticuerpos anti-pd-l1.
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
MX388181B (es) Anticuerpos anti-pd-1.
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
MX2018008995A (es) Combinacion de un agonista de ox40 y un agonista de 4-1bb para tratar el cancer.
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
ZA201708265B (en) Tigit-binding agents and uses thereof
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
LT3394103T (lt) Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
EA201890175A1 (ru) Антитела к cd40
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
PH12018502502A1 (en) Anti-gitr antibodies and uses thereof
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
MY192999A (en) Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
EA201790834A1 (ru) Молекулы антител к pd-l1 и их применение
BR112016027881A2 (pt) antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv
EP4681733A3 (en) Anti-ceramide antibodies
EA201791970A1 (ru) Способ лечения первичного склерозирующего холангита
MX2017015311A (es) Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.